| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Allogene Therapeutics Inc (NASDAQ: ALLO)
ALLO Technical Analysis
5
| As on 9th Jun 2023 ALLO STOCK Price closed @ 5.64 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 11.08 & Strong Sell for SHORT-TERM with Stoploss of 11.85 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ALLOSTOCK Price
| Open | 5.80 | Change | Price | % |
| High | 5.85 | 1 Day | -0.16 | -2.76 |
| Low | 5.60 | 1 Week | 0.11 | 1.99 |
| Close | 5.64 | 1 Month | 0.04 | 0.71 |
| Volume | 712857 | 1 Year | -10.17 | -64.33 |
| 52 Week High 17.28 | 52 Week Low 4.53 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| ALLO Daily Charts |
ALLO Intraday Charts |
Whats New @ Bazaartrend |
ALLO Free Analysis |
|
|
ALLO Important Levels Intraday
| RESISTANCE | 6.12 |
| RESISTANCE | 5.97 |
| RESISTANCE | 5.87 |
| RESISTANCE | 5.78 |
| SUPPORT | 5.50 |
| SUPPORT | 5.41 |
| SUPPORT | 5.31 |
| SUPPORT | 5.16 |
ALLO Forecast May 2024
| 4th UP Forecast | 15.16 |
| 3rd UP Forecast | 12.11 |
| 2nd UP Forecast | 10.22 |
| 1st UP Forecast | 8.33 |
| 1st DOWN Forecast | 2.95 |
| 2nd DOWN Forecast | 1.06 |
| 3rd DOWN Forecast | -0.83 |
| 4th DOWN Forecast | -3.88 |
ALLO Weekly Forecast
| 4th UP Forecast | 8.18 |
| 3rd UP Forecast | 7.37 |
| 2nd UP Forecast | 6.86 |
| 1st UP Forecast | 6.36 |
| 1st DOWN Forecast | 4.92 |
| 2nd DOWN Forecast | 4.42 |
| 3rd DOWN Forecast | 3.91 |
| 4th DOWN Forecast | 3.10 |
ALLO Forecast2024
| 4th UP Forecast | 30.83 |
| 3rd UP Forecast | 22.75 |
| 2nd UP Forecast | 17.76 |
| 1st UP Forecast | 12.76 |
| 1st DOWN Forecast | -1.48 |
| 2nd DOWN Forecast | -6.48 |
| 3rd DOWN Forecast | -11.47 |
| 4th DOWN Forecast | -19.55 |
Allogene Therapeutics Inc ( NASDAQ USA Symbol : ALLO )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ALLO Business Profile
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was founded in 2017 and is headquartered in South San Francisco, California. Address: 210 East Grand Avenue, South San Francisco, CA, United States, 94080
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service